gc012f
gracell biotechnologies
['hodgkin', 'gc012f ', 'lymphoma', '$grcl', 'gracell']
$grcl gracell biotechnologies presents longer-term results for fastcar-t gc012f in b-cell non-hodgkin's lymphoma at eha2023, highlighting 100% overall response rate. data on cd19/bcma dual-targeting fastcar-tgc012f showed 100% overall response rate (... 
Financial news recaps and ticker rating curated by AI language models. Fine tuned on analyst articles and return alpha. More exposure to lesser known companies.